 Duration of Subject Participation: Subjects will receive either divalproex sodium extended release Depakote-ER or matched placebo for 12 weeks. Subjects will continue to receive other treatment as usual within the Addiction Treatment Center in accordance with their ongoing clinical program treatment plan. The standard expectation within the context of treatment as usual is for at least 6 months of treatment involvement. A limited number of psychotropic medications will be allowed during the study. A benzodiazepine usually chlordiazepoxide or lorazepam, in accordance with standard practice and generally given in an as needed symptom triggered manner can be prescribed during the acute detoxification period first 7 days. Hydroxyzine can be prescribed PRN for anxiety, and zolpidem PRN not to exceed 5 nights per week for insomnia, throughout the course of the study. 